title: Dienogest and the breast.
abstract: In a clinical pilot study, 21 women with endometriosis have been primarely treated with dienogest 2 x 10 mg daily p.o. for 24 weeks. Besides the effect on endometriosis the action of such high-dose progestogen treatment on the breast was evaluated by breast ultrasound prior to medication and at 24 weeks of medical treatment. In all women, a significant size reduction of the mammary gland (p < 0.023) and regression of mastopathic changes were observed. There was a non-significant reduction (p = 0.089) of the maximum diameter of the ducts. The portion of the fatty tissue increased slightly, but not significantly (p = 0.348).
authors.affiliation: Institute for Medical Research and Education, Hufelandstrasse 55, D-45122 Essen, Germany. adolf.schindler@uni-due.de
authors.forename: Adolf E
authors.initials: AE
authors.lastname: Schindler
authors.forename: Alexandria
authors.initials: A
authors.lastname: Henkel
authors.forename: Bernd
authors.initials: B
authors.lastname: Christensen
authors.forename: Michel
authors.initials: M
authors.lastname: Oettel
authors.forename: Claudia
authors.initials: C
authors.lastname: Moore
mesh_terms: D000328:Adult; D001940:Breast / Q000187:drug effects*; D004715:Endometriosis / Q000188:drug therapy*; D005260:Female; D005348:Fibrocystic Breast Disease / Q000000981:diagnostic imaging / Q000188:drug therapy*; D006727:Hormone Antagonists / Q000008:administration & dosage*; D006801:Humans; D009277:Nandrolone / Q000008:administration & dosage / Q000031:analogs & derivatives*; D010865:Pilot Projects; D016217:Ultrasonography, Mammary; D055815:Young Adult
chemical_list: D006727:Hormone Antagonists; C023635:dienogest; D009277:Nandrolone